In a recent development, the FDA has granted approval for a next-generation Covid vaccine from Moderna, albeit with certain restrictions in place. The approval letter mandates Moderna to conduct a new randomized controlled trial targeting adults aged 50 to 64, to ascertain the ongoing efficacy of Covid vaccination in this age group. Furthermore, a commentary published in the New England Journal of Medicine by FDA Commissioner Marty Makary and Vinay Prasad, the new head of the FDA’s vaccines division, questions the continued benefits of Covid shots for individuals not at high risk of severe infection. As a result, future use of the vaccines is expected to be focused on high-risk groups and individuals aged 65 and above. These developments underscore the evolving landscape of vaccine development and distribution, as regulatory bodies strive to optimize the effectiveness of Covid vaccination campaigns.
Read more about this — here
